Synopsis: Anthem Biosciences Limited posted strong Q4FY26 growth, with its CRDMO business contributing nearly 84 percent of total revenue and remaining the company’s key growth driver.
This Mid-cap Healthcare Stock, engaged in contract research, development, and manufacturing services for pharmaceutical and biotechnology companies across drug discovery and commercial production activities, jumped 4.15 percent after the company reported March quarterly results with a 128.92 percent YoY increase in net profit.
With a market capitalization of Rs. 43,086.26 crores, the share of Anthem Biosciences Limited has reached an intraday high of Rs. 819.75 per equity share, rising nearly 4.15 percent from its previous day’s close price of Rs. 787.10. Since then, the stock has retreated and is currently trading at Rs. 767.05 per equity share.
Q4 FY26 Result Walkthrough:
Coming into the quarterly results of Anthem Biosciences Limited, the company’s consolidated revenue from operations increased by 26.50 percent YOY, from Rs. 483 crore in Q4 FY25 to Rs. 611 crore in Q4 FY26, and grew by 44.44 percent QoQ from Rs. 423 crore in Q3 FY26.
In Q4 FY26, Anthem Biosciences Limited’s consolidated net profit increased by 128.92 percent YOY, reaching Rs. 190 crore compared to Rs. 83 crore during the same period last year. As compared to Q3 FY26, the net profit has increased by 104.30 percent, from Rs. 93 crore.
The basic earnings per share increased by 128.38 percent and stood at Rs. 3.38 as against Rs. 1.48 recorded in the same quarter in the previous year, FY2025.
Dividend: Anthem Biosciences Limited’s board of directors has recommended paying a final dividend at the rate of 100 percent on the face value of paid-up equity shares of Rs. 2 each for the financial year 2025-26, which is a dividend of Rs. 2 per equity share. The record date for the purpose of payment of the final dividend is Friday, June 26, 2026.
Annual Performance of FY26:
Anthem Biosciences Limited’s revenue has increased from Rs. 1,845 crore in FY25 to Rs. 2,124 crore in FY26, which has grown by 15.12 percent. The net profit has also grown by 31.26 percent from Rs. 451 crore in FY25 to Rs. 592 crore in FY26. The annual basic earnings per share increased by 30.61 percent and stood at Rs. 10.54 as against Rs. 8.07 recorded in the financial year 2025.
Anthem Biosciences Limited’s revenue and net profit have grown at a CAGR of 26.19 percent and 15.42 percent, respectively, over the last three years. In terms of return ratios, the company’s ROCE and ROE stand at 30.4 percent and 22.3 percent, respectively. Anthem Biosciences Limited’s debt-to-equity ratio is 0.02x.
Revenue Mix (FY26 & Q4 FY26)
Anthem Biosciences Limited earns most of its revenue from its CRDMO (Contract Research, Development, and Manufacturing Organization) business. In FY26, the CRDMO segment contributed around Rs. 1,773 crore, accounting for 83.45 percent of total revenue, while the Specialty Ingredients business contributed nearly Rs. 352 crore, making up 16.55 percent of revenue.
The company maintained a similar revenue mix in Q4FY26. The CRDMO business generated approximately Rs. 513 crore, contributing 83.94 percent of quarterly revenue, whereas the Specialty Ingredients segment delivered around Rs. 98 crore, accounting for 16.06 percent. This consistent revenue mix highlights Anthem Biosciences’ strong dependence on its CRDMO operations as the key driver of growth and overall business performance.
New Greenfield Expansion:
Anthem Biosciences Limited is expanding its manufacturing capacity through a new greenfield facility at its 30-acre site in Harohalli, Bangalore. Under Phase I of Unit IV expansion, the company is investing around Rs. 1,200 crore to add 365 KL of Custom Synthesis capacity and 100 KL of Fermentation capacity. This expansion is expected to strengthen the company’s production capabilities and support future growth in its CRDMO business.
Company Overview:
Anthem Biosciences Limited was founded in 2006 and is an India-headquartered biotechnology Contract Research, Development and Manufacturing Organization (CRDMO). It provides end-to-end services across the drug lifecycle for global pharmaceutical and biotech companies, spanning discovery through commercial manufacturing of small and large molecules.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Anthem Biosciences Results: Which Segment Contributed the Highest Revenue in Q4? appeared first on Trade Brains.